Neil Chatterji
Stock Analyst at B. Riley Securities
(1.68)
# 3,424
Out of 5,161 analysts
20
Total ratings
33.33%
Success rate
2.75%
Average return
Main Sectors:
Stocks Rated by Neil Chatterji
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLPT ClearPoint Neuro | Maintains: Buy | $28 → $18 | $11.53 | +56.11% | 5 | Mar 5, 2026 | |
| OPRX OptimizeRx | Maintains: Buy | $17 → $13 | $5.93 | +119.22% | 3 | Dec 24, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $95 → $50 | $63.60 | -21.38% | 2 | Nov 9, 2023 | |
| ARAY Accuray | Reiterates: Buy | $7.5 | $0.42 | +1,686.14% | 1 | Oct 4, 2023 | |
| ZUMZ Zumiez | Maintains: Neutral | $15 → $18 | $23.44 | -23.21% | 2 | Sep 8, 2023 | |
| KRMD KORU Medical Systems | Initiates: Buy | $4.5 | $4.31 | +4.41% | 1 | Sep 7, 2023 | |
| HYPR Hyperfine | Maintains: Buy | $2.5 → $3.5 | $1.17 | +199.15% | 3 | Aug 15, 2023 | |
| STXS Stereotaxis | Maintains: Buy | $6 → $5.5 | $1.88 | +192.55% | 2 | Mar 6, 2023 | |
| BFLY Butterfly Network | Initiates: Buy | $9.5 | $3.64 | +160.99% | 1 | Oct 4, 2022 |
ClearPoint Neuro
Mar 5, 2026
Maintains: Buy
Price Target: $28 → $18
Current: $11.53
Upside: +56.11%
OptimizeRx
Dec 24, 2024
Maintains: Buy
Price Target: $17 → $13
Current: $5.93
Upside: +119.22%
Establishment Labs Holdings
Nov 9, 2023
Maintains: Buy
Price Target: $95 → $50
Current: $63.60
Upside: -21.38%
Accuray
Oct 4, 2023
Reiterates: Buy
Price Target: $7.5
Current: $0.42
Upside: +1,686.14%
Zumiez
Sep 8, 2023
Maintains: Neutral
Price Target: $15 → $18
Current: $23.44
Upside: -23.21%
KORU Medical Systems
Sep 7, 2023
Initiates: Buy
Price Target: $4.5
Current: $4.31
Upside: +4.41%
Hyperfine
Aug 15, 2023
Maintains: Buy
Price Target: $2.5 → $3.5
Current: $1.17
Upside: +199.15%
Stereotaxis
Mar 6, 2023
Maintains: Buy
Price Target: $6 → $5.5
Current: $1.88
Upside: +192.55%
Butterfly Network
Oct 4, 2022
Initiates: Buy
Price Target: $9.5
Current: $3.64
Upside: +160.99%